PIK3CA Mutation trials recruiting in Texas

All PIK3CA Mutation trials nationally

Cities in Texas

Recruiting trials in Texas

• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Houston
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Austin, Dallas, Houston, Temple
• Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
  NCT07524322 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Houston, San Antonio